Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN-1792 in mild to moderate Alzheimer's disease
NCT00021723Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2001
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AN-1792 in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Sep 2001; status: terminated.
02
Drugs
AN-1792
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00021723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021723.